Ignite Creation Date:
2025-12-24 @ 1:13 PM
Ignite Modification Date:
2025-12-30 @ 8:44 PM
Study NCT ID:
NCT04807595
Status:
COMPLETED
Last Update Posted:
2023-03-06
First Post:
2021-03-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-05-28
Start Date Type:
ACTUAL
Primary Completion Date:
2022-04-26
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-04-26
Completion Date Type:
ACTUAL
First Submit Date:
2021-03-18
First Submit QC Date:
None
Study First Post Date:
2021-03-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-03-03
Last Update Post Date:
2023-03-06
Last Update Post Date Type:
ACTUAL